Complex Chronic Diseases Appear to Drive Frequent Admissions

This article originally appeared here.
Share this content:
Complex Chronic Diseases Appear to Drive Frequent Admissions
Complex Chronic Diseases Appear to Drive Frequent Admissions

WEDNESDAY, Sept. 16, 2015 (HealthDay News) -- Patients who are frequently admitted to U.S. academic medical centers are significantly more likely than other patients to have multiple complex chronic conditions, according to a study published in the September issue of the Journal of Hospital Medicine.

Marilyn K. Szekendi, Ph.D., from University HealthSystem Consortium in Chicago, and colleagues analyzed data from a comprehensive administrative database (University HealthSystem Consortium's Clinical Data Base/Resource Manager) to identify demographic, social, and clinical characteristics of frequently admitted patients in 101 U.S. academic medical centers.

The researchers found that 28,291 frequently admitted patients (1.6 percent of all patients) had 180,185 admissions (8 percent of all admissions) over a one-year period (2011 to 2012). These patients comprised 7 percent of all direct costs, and their admissions were driven by multiple chronic conditions. Compared with other hospitalized patients, they had significantly more comorbidities (an average of 7.1 versus 2.5), including significantly more diagnoses of psychosis or substance abuse. They were slightly more likely than other patients to be on Medicaid or to be uninsured (27.6 percent versus 21.6 percent).

"Frequently admitted patients' diagnoses and procedures suggest that their admissions were related to complex chronic diseases; more than three-quarters were admitted to medicine services, and their average length of stay was nearly 7 days," the authors write. "This information can be used to identify solutions for preventing repeat hospitalization for this small group of patients who consume a highly disproportionate share of health care resources," they conclude.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths